FDA takes closer look at AZ's saxagliptin

Share this article:
Onglyza
Onglyza

The FDA is looking into a possible association between type 2 diabetes medication saxagliptin and heart failure. The drug was not associated with a higher risk of death.

Saxagliptin, also known as Onglyza and Kombiglyze XR, was initially part of a Bristol-Myers Squibb/AstraZeneca alliance. AZ took full ownership of products from the now-former joint venture late last year.

The regulator announced the investigation Tuesday, citing a study in the New England Journal of Medicine published in 2013 that found that more saxagliptin patients were hospitalized for heart failure than were placebo group patients.

Saxagliptin was not linked with a higher rate of stroke, which was another study endpoint.

The FDA said in a statement that it is not advising patients to stop using saxagliptin, nor is it asking doctors to stop prescribing the DPP-4 medication.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.